David Ahmadzai - 15 Mar 2022 Form 4 Insider Report for NEXTGEN HEALTHCARE, INC.

Role
Chief Accounting Officer
Signature
/s/ Jeffrey D. Linton, Attorney-in-Fact for David Ahmadzai
Issuer symbol
N/A
Transactions as of
15 Mar 2022
Net transactions value
-$18,511
Form type
4
Filing time
16 Mar 2022, 16:44:12 UTC
Previous filing
04 Nov 2021
Next filing
02 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NXGN Common Stock Options Exercise $53,202 +3,250 +7.3% $16.37 47,772 15 Mar 2022 Direct
transaction NXGN Common Stock Options Exercise $50,490 +3,000 +6.3% $16.83 50,772 15 Mar 2022 Direct
transaction NXGN Common Stock Sale $122,203 -6,250 -12% $19.55 44,522 15 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXGN Stock Option (right to buy) Options Exercise $0 -3,250 -35% $0.000000 6,000 15 Mar 2022 Common Stock 3,250 $16.37 Direct F2
transaction NXGN Stock Option (right to buy) Options Exercise $0 -3,000 -50% $0.000000 3,000 15 Mar 2022 Common Stock 3,000 $16.83 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.55 to $19.561. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request.
F2 Original grant of 13,000 options granted on 6/13/2017 vested in four equal, annual installments beginning 6/13/2018.
F3 Original grant of 12,000 options granted on 5/30/2018 vests in four equal, annual installments beginning 6/1/2019. Options exercised vested on 6/1/2021. Remaining 3,000 options will vest on 6/1/2022.